Acute megakaryoblastic leukemia laboratory findings

Acute megakaryoblastic leukemia Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Acute megakaryoblastic leukemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Acute megakaryoblastic leukemia laboratory findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Acute megakaryoblastic leukemia laboratory findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Acute megakaryoblastic leukemia laboratory findings
CDC on Acute megakaryoblastic leukemia laboratory findings
Acute megakaryoblastic leukemia laboratory findings in the news
Blogs on Acute megakaryoblastic leukemia laboratory findings
Directions to Hospitals Treating Acute megakaryoblastic leukemia
Risk calculators and risk factors for Acute megakaryoblastic leukemia laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Laboratory Findings

The diagnosis of AMKL (M7) is based on the following:

1. Bone marrow biopsy demonstrating 30% or more leukemic cells of megakaryocytic lineage
2. Conducting tests that detect platelet-specific antibodies which could be monoclonal or polyclonal.
3. Bone marrow biopsy is recommended in patients who developed myelofibrosis. Visualization of blasts and mature megakaryocytes on biopsy sections is diagnostic.